ROCHESTER, N.Y., March 26, 2015 – Vaccinex, Inc. today announced that it will present additional preclinical data on its anti-Semaphorin 4D program at the American Association for Cancer Research conference in Philadelphia, PA on April 19th.
Vaccinex representatives will be on hand to present information about its first in class anti-Semaphorin 4D immunomodulatory antibody discovered, characterized, and tested successfully by Vaccinex in preclinical models of oncology and in a phase 1 trial of patients with advanced solid tumors. Blockade of SEMA4D in preclinical testing has been shown to delay tumor growth and in some cases cause durable regression either alone or in combination with checkpoint blockade inhibitors. In preclinical studies, anti-Semaphorin 4D has been shown to facilitate migration of activated immune cells into the tumor microenvironment. Vaccinex is using this information to design and conduct clinical trials.
Update (4/27/2015): Download the poster here.
About Vaccinex, Inc.
Vaccinex, Inc. is a privately held clinical-stage immunotherapy company engaged in the discovery and development of human therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases, including multiple sclerosis and Huntington’s Disease. Vaccinex utilizes its proprietary ActivMAb® Antibody Discovery Technology for rapid, mammalian cell-based antibody selection to build its antibody pipeline and in service to its biopharmaceutical partners. Compared to other selection technologies, ActivMAb® combines the advantages of rapid and sensitive selection by virus panning and cell sorting in one technology, with intrinsic selection of antibodies that are efficiently expressed and stable in mammalian cells. Vaccinex is based in Rochester, New York. For more information and to contact Vaccinex, visit www.vaccinex.com.